Actual Coronavirus Testing Options Examined

Executive *******

* *********** ********** ********* exist:

• ***/*********, *** **** ******** but *** **** ****** and **** ****-*********.
• ***** *********, ******, *** Antigen *** *** ****** accurate ****** **** ******** than ***/********* *** *** be **** **** ** a ******* **** ***** (~15 *******).
• ***** ******* *** **** less ******** (**** ************ people **** ****** ******* and ********** **** ****) but ***, ** ***, the *******.

**** ***** ***** *** varying ********** ******* *** approaches:

********* *** ***** *** been ******* ** ** now, ****** *** ****** ***** ** **** to ***** **** ** see ***** **** ****** the **** ******. ** addition, ******** ***** ***** that **** ** ******* had *** *********** *** cannot ******** **.

Asymptomatic *** ************** ******

****** ***** *******, *********** tests *** ******** ** detect ***** **** *** virus **** ** **** are ************ ** **************. People ***** **** ********** ** the *** **** ****** symptoms.*** ****** ********* **** ******* 80%** ****** **** **** cases ** *** ************. So, **** ********** ****** may *** **** ********. This ***** *********** ***** can ***** **** ********** individuals **** ***** ******* will ****.

Common *********/*** ****/***** ****/******* **** *************

*** **** ****** **** type ** *********/*** ***** which ********* ********, *********, ****, uncomfortable, *** ****** **** supply *********. **** *** ********* the **** ******** ****** for ********** *********** *** are *** ****** *** screening ** ******** *******. They *** ******* **** Amplification ** ******* *** amount ** *********** ** a ******, ****** **** more ********. ***, ************* causes *** ***** ** be *********, ********-*********, *** time-consuming. * *** ***** process * **** ** an ****, *** ******* need ** ** ***** to *** *** *** backlogs *****, ******* ******* to ***** **** **** after *******. **** *** also ************* ******* * nasal **** ***** ** be ******** **** **** the ****. ****,****-************ ******** *** ** ******** as ************** ************, ******* people ** *** *** the **** *** ****** up ***** *****. **** means ******** ******* ******** medical ************* *** ****** be *******-****. ** ** unclear *** **** ***** tests **** ** ************** carriers, *** **** *** currently *** **** ******** option.

*** *******,*** *** *** ***** PCR ********* *** '******'.

Debate **** **** ** * ******** ******

***** *** ***** *** the **** ********, ******* debate ****** **** **** level ** ******* ****** count ** ******** ******* for ***********.*** ******* *** ******** by*** ****** ** ************* cycles (**) ******** *** the ***** ** ** detected. ***** ******* **** more *****, *** * decrease ** ** ** 1 *********** ** * roughly ******** ** *** viral ****. **, * CT ** ** ***** someone *** ******* ***** the *********** **** ** a ** ** **. This **** ******* ***** that *** ******* **** amplification. **** ***** ***** any ***** ***** ** as * ******** ******, but**** ***** **** ** too****.* ****-******** ***** ********* **’* ***** ** was *** *** *** the ***** ** ********* in * ***, ********* that ***** ****** **** not **********. ***, ****** **** ***** ******** that******* ******* *********** ***** cutoffs ** **-** ** below **. **** ** significant, ******* * ******** of ******** ******* *** be **** *********** *** are ** ****** **********, who **** **’* ***** 30 ** **. ** means **** ********* *** being ****** ** ******* tracing *** ********* *** people *** *** ** longer **********.

FDA ********** ****** ******* ** ******** ************

*** *** *** *** is ************ ******** ******* ************ is ****** *** *******, where ******* ******* *** combined *** *** **** individually ****** ** *** batch ***** **** ********, but **** **** ***** if *********** ***** *** low (***** **** **** less **** *% ** tens ** *******). ******* allows ******** ******* ** be ********* ** ****, hypothetically ********** *** ******* capabilities ** *** *.*. But, ** *** ******** rate ** *** ****, enough ***** **** ** be ****** ************ **** pooling ******** ********* ******* capabilities *** **** *****. While ******* *** ****** in **** *****, **** positive ***** ******** ** ***************** ** parts ** *** *.*.

Rapid *** *****

***** ***** *** ***** are ******* ** *********** PCR ***** *** ********* on * ******* *****, so ******* *** ******* and ***** ** **** for *********.***** ***** ***** *** less ******** **** *********** PCR ******** * ******** ****** does *** *********** **** out ***********.** ******* (**-** *******), ***********, and *** ** **** with ******** *********.

Rapid *** **** ************

*** *** *** ************ ***** ***** *** tests, ********* *** ** home, *** ************ *** *** ********** ************* ********** ********, however, ************ *** ** limited. ********* ********** *** ********* *** authorization *** ** ************ only. *** ***** ***** overviews *** ******* *** the ****** ****:

*******, *** **** ******** a ************ *** ******** time, **, ***-**-*** **** could **** ** ***** or ****. ****** *** ***** ***** is **** *** **** may *** ** *********.

*** **** ******* ****:

****** ****** **** *** tests **** ******** ** initially **** *** ** California *** ******* "** the **** ******." *** kits **** **** ** widely ********* ****** *** country ** ****** **** at * ***** *** of $**.

Saliva ***** ********* *****

******-***** ********* ***** *** being ******** ** ** inexpensive, ****, ****** ******** solution **** *** ** used *** ********* *** accuracy ** ******.** *** *******, *** best **** ******************** ******* *** ***** and *** ***** ********* similarly ** ******* ***** PCR *** ******* *****, indicating ******** ****** ******* and ** *** ** good ** *** **** PCR *****. **** *** fast (*-** *******) *** could **** **** **** $1 ****** **** **** accessible. **** *** **** reliant ** ******** *********, which ***** ******* ****** shortages. ****, ****** ***** are *********** *** ******* are **** *** ****** to **** **********. **** means **** ** ******* testing ** ********, *** health ************* *** *** needed *** **********. ** also ***** **** ****** who ******* ***** ***** and ***** ***** **** require **** ***** *** tested **** ******-***** ********* tests.

Saliva **** ************

***** ***** ******-***** ***** **** FDA***,* **** ************* *************, **** ********* *** *** selling**-**** ***** ** *** U.S.****, *** *.*. *****,********* ** ******** ********** ***** ** ********* who ******* **** *** have ***********, ** ******* locations ****** *** *****.

Antigen *****

******* ***** **** ****** accuracy *** *** ****** and ******* **** *** tests *** *** ** done ******* *** *** equipment.******* **** ******** ********** **% - **% in ********** ********, ** it ** ********* ** know **** **** *** is *****. **** **** for ******** ********** **** coronavirus *** ** *** involve *************. ***** *** displayed ** * **** strip, **** **** * pregnancy ****, *********** *** need *** ********* ********* or ******* *************.

Antigen ******* ************

***** *** ********** ******* ***** **** FDA ***,** **** ************* ***********************, *** **** ****** for ***** *****. * of *** * ******* tests **** ******** ** October *** **** *** approved *** **-**** ***. And,*** *.*. ********** *** purchased *** ************ ******* ***** ** increase *** *********** ******* capabilities ** *** ****** State **** ***** ****. However, ****** *** ***** tests ** **** *** they *** *** ** available.

Benefits ** **** ******** ***** *******

*********** ***** ***** *** find ***** *********** *** testing ***** **** ******* traditional *** ***** *** too ****, ******-***********, *** cost-prohibitive *** ******** *******. They *** **** ** used *** *********, ***** could **** **** ********* facilities. ************** *** ************ individuals **** ** **** likely ** **** ***** tests, *** ***** *********** are *** **** ********* people ** ****. **** if **** *** **** accurate **** *********** *** tests, ***** ***** *** more ******** **** ** testing. *******, **** ** a **** ****** * case, * ******-** **** could ***** **. *********** PCR ***** *** *** inaccessible *** ******** *******, but **** ** ***** rapid ***** ***** ** taken ********** ** ****** populations. ****** *** ***** molecular, ******, ** ******* tests *** *** ***** may ** **** ******** than * ****** *********** molecular ****, *******, **** accessible, *** ***** **** a ********** ****** ** time. ****, *** ********** in ******** *** ** overstated ******* ** *** high ** ********* *** tests **** ******* **** Amplification ***. ******** *** results **** **-****** ********** individuals *** ** *********** counted ** ***** ********* for ***** *******, ******* of ***** ********* *** PCR *****.

Slovakia, ** *** **** ***** *******

******** *** *** ***** **** ******* *******, uncovering ********* ** *** cases. ** ********, */**** of *** **********, ****** everyone ******* **-**, (*.* million ******) **** ****** on *** ******* ** October **** ***** ***** antigen *****.**** ******* ********* **,*** new *****, ****** ** **** as *** **,*** ******** PCR ******* *** ***** since *** ***** ** the ********. ***** ************ ******* **** antigen******* ** *********, ***** they ****** **** ********* uncovering *** *** *******-**** cases, *** **** ** expanding **** *******.

NBA **** ***** ******* ***** **** ******** ** ******

**** ******, *** ****** CEO, **** ***** ******* ***** ******* could ***** **** ** attend *****:

* ** ***** **'* realistic ... ***** **** been *********** ************ ** rapid ******* ***** *** onset ** *****-**. **'** fairly ********** **** *** market **** ******** **** and ****** ***** ** faster *******. ***** *** be ************* ** *** context ** ** *****, particularly ** *** ***** bowl, ***** ***** ** an ******** ***** **** allows *** **.

Antibody *****

********/***** ***** ****** ***** someone *** *********** ** the ****,*** **** *** *** used ** ******** ****** cases. ******** ***** *** fast *** ********** ******** but **** ** *** work **** ***** *-* weeks ***** *********** ***********. In ********, ***** ** no *** ** *************** between ******* *** *** an ****** ********* *** someone *** *** ** active ********* ** *** past. **** ***** ******** tests *** *** *********** useful ** ***********. ******** tests *** * **** way *** ****** ****** officials ** ******** *** percent ** * ********** that *** *********** ** the ****, ******** ********* to ****** ****** ******* models.

** ** ********* ** remember **** * ******** result *** ******** ** active *********, ** ****** should *** ***** * positive ****** ** ********. Do *** *** **** you ****** ****** ***********, just ******* *** **** a ******** ******** ****.

Cough *****

** *** **** ********** * ***** ***** test **** *** ******** ~97% ********** ********** ***** *** works ** ************ ********. The **** ******** **** the **** **** ********** intelligence ** ******* ****** coughs. **** *** **** achieved * **.*% **** positive **** * **% true-negative **** ** ********** who *** ***** ********* PCR *****. ***, **** they **** **** ** achieve * ***% **** positive **** ** ************ patients **** * **% true-negative ****. **** ** more ******** **** **** of *** ***** ******* methods *********. *** **** does *** ******* ******* or ******* *****, *** will *** **** ** noises **** *** *** cough. *******, *** **** noted **** ****** *** affected ** ********, ***, and ******* ** ******* could ****** **** ********* demographics:

***** ***** *** ******** and *** *********** ** coughs, ****** **** ***** also ***** ** ********* the ***** ** ********* age ****** *** ******* of *** ***** ***** the ******** ********, *** possibly ********* ***** ****** or ***** ********** **** as ****** ** ******* language ******* ************

*** **** **** **** are ********** **** * Fortune *** ******* *** more ******* *** **********. This ***** ** **** into ** *** *** mass *** *********** **** screening *** ** *** currently ********** ********* ** FDA ********.

How *** * *** ******?

******* *** ** ******** through ****** ****** ******, private ******* *******, *** certain ********.***** *** ******* ***** distributed ********** ** ******* centers ** ******* ******* systems ***** **** ***** require *************. ** ********,* ************ ******* **-**** ***** (PCR ** ******) **** you **** **** *** a ****** ** *** U.S. **** **** ******* $109-$155 ********* ** ***** ******* by ************** *** ***** ***. However,*********** **** ***** ****-************** ***** ** ** less ******** **** ****-********* swabs, **, *** ** a *** *******, ******** could **** *** ** improper *********.** ********, ******* **** centers *** ******* *****.

**** ** ***** ******* are ** ******** *** to ********* ********* ***** for ***** (****** ***** to ** ****-******).******* ** ******* ** at ***** ** ********** *** *.*. *** 10 **** ****** *** world.******* ****** ** ******** a******* ** *** ********* travelers **** * ***** test ******* ** * full **-*** **********. ** addition,**** *** ***** **** to ****** ************ *** *** *** Helsinki-Vantaa *******.

Example ** ***** *** ***** **** ** ** ****** ** ***** ****: *********, **, ***

******* ** ************ ************ * ****** ****** for ************ *** *** state **** ** **** tests ********** ** *** who **** ****. ** get ****** ** ************, residents ****** ****** **** out ****** ******* *************. ***** ******** *** symptoms, ** ** **** are *******, **** *********** *** **** ******** *** **** ******** they ****. *******, **** should ****** *********** ***** **** ****** ******* centers ** ******** * test. *** ******* **** to *** **** ******* facility ** *** ************ Avenue ***.*** **** *** * questionnaire** ********* ***********, *** currently, **** ****** ** risk, **** ********, **** factors, ** ******** ******** are ******** *** *******.*** **************-*** ******* *** ***** tests (***** **** ******* availability) *** *-* *** typical **** ***** *** lab *****, **** *** tests. **** **** ***** tests **** “********* *******”, and * ***** **** was *** ********* *** a ******* **** ***** and ******** ********, **** Bethlehem. *******, ***** **** 24 ****** ********* *** a *** ****, **** expected **** ***** ** 2-3 ****.

Corporate *********

** ** ******** *** large ************ ** ****** relationships **** **** (** their *** ***) *** at ***** *** ******* is ********* ***** ** smaller ************.***** ******** *** ************* *** **** ****** and ***** ****, ** ensure ***** ********* *** get ******, ********* ***** *** *** lab *** ******** *** ******* **,*** tests * ***, *** *** ******* companies, ***** *** ***** options. ** *** **,********* ********* ******* *********** solutions ********* *** *** antibody *****. *******'* ******** will ****** **** **** than ********** ***** ******* of ****, *** **** still ** ********** *********, take ******* **** ** process, *** ** **** at ****, ******** *** suffer *** ** ******** sample **********.

More ***********

**** ** ******** ** a ******* ************. *** more *********/******* ****, **** at ********** *** ********** New *********** (****) * *** ************* non-profit **** ** ******** Coronavirus ***** *** ********* their ********. ****, *** accuracy ** ********* **** real-life ********, ***** ******** complicated **********.**** *** ******* ******* of ******** *************** ******** ** ******* and *** * ***** that *** **** *** interpret **** * ******** test ****** ***** ***** on *** ****'* ******** and **** ********** ** being ********.

*******

**** ******* ******* ********* thousands ** ******* ***** in ******** *** *** UK, ** **** ********* may ******* **** ***** testing. ******* ******** ********* is ***** ***** ****, although *** *** **** they *** *********** ** to ****** ********. ***,*** ******** **** ***** promising ********* *** ***** ****** of *******, ********* *** pandemic ***** ** ********** in *** **** ****.

[**** *** ********** ****** in ****** **** *** substantially ******* ** ******** 2020 ** ******* *** developments.]